Breaking Ground in Neurorehabilitation: Helius Medical s PoNS Device Gains Momentum with New Reimbursements and Clinical TrialsNewtown, Pa. April 24, 2024 Helius Medical Technologies, Inc. (Nasdaq:HSDT), a pioneering neurotech company, is making significant strides in advancing neurorehabilitation through its Portable Neuromodulation Stimulator (PoNS) device. Recent developments have bolstered the company s positioning as a leader in treating balance and gait deficits, especially for individuals recovering from traumatic brain injuries and strokes.
Advances in Reimbursement Approvals
In a significant milestone, Helius announced that United Healthcare has joined Anthem as the second major healthcare provider to approve reimbursement claims for the PoNS device. The PoNS device is now reimbursed at an out-of-network adjusted list price, which marks a pivotal turning point for the company by expanding access for patients seeking this innovative therapeutic solution.
The Centers for Medicare & Medicaid Services (CMS) have also updated reimbursement payment determinations for the PoNS device components. Specifically, the reimbursement for the PoNS Mouthpiece (HCPCS code A4594) has been set at a lump-sum payment of $2,963.30. Though Helius has announced intentions to challenge this determination to potentially secure more favorable terms, it is a step forward in defining the economic landscape for this cutting-edge technology. Additionally, the national reimbursement payment determination for the PoNS Controller will be reconsidered in the next cycle, demonstrating ongoing dialogues between Helius and regulatory bodies.
Expansion of Stroke Clinical Programs
Beyond financial milestones, Helius is propelling forward with significant clinical advancements. With its recent partnership with the Shepherd Center, Helius expands its U.S. registrational program to include stroke patients. This alliance marks an essential chapter for evaluating the efficacy of the PoNS device in treating gait and balance deficits among chronic stroke survivors. The Shepherd Center, renowned for its breakthrough innovations and exceptional patient outcomes, adds a robust layer of validation and credibility to the study.
This single-arm study will complement the ongoing research activities already underway with Brooks Rehabilitation, making Shepherd Center the third clinical site involved. Under the leadership of Dr. Michael Yochelson, the initiative aligns with the company s goal to broaden the PoNS device labeling by securing regulatory marketing authorization for stroke, expected in 2025.
Navigating the Future of Neurorehabilitation
Helius Medical Technologies is keen on redefining therapeutic strategies for neurological disorders. By integrating both reimbursement avenues and rigorous clinical evaluations, the company aspires to make substantial impacts on patient well-being across multiple neurological conditions. The anticipated regulatory submissions in 2025 reflect Helius s commitment to not only compliance and regulation but also to innovation in medical technology that has the potential to transform lives.
As the company continues to advance its agenda in both clinical and policy realms, stakeholders in healthcare and technology should closely monitor these developments. Helius’s expansion reflects a broader trend towards non-invasive solutions in managing complex neurorehabilitation, and the results of these endeavors could set new standards in the field.
Comments